​

Harmony Biosciences (HRMY) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

HRMY Stock Forecast

Harmony Biosciences (HRMY) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $45.33, with a high of $56.00 and a low of $28.00. This represents a 16.77% increase from the last price of $38.82.

$25 $32 $39 $46 $53 $60 High: $56 Avg: $45.33 Low: $28 Last Closed Price: $38.82

HRMY Stock Rating

Harmony Biosciences stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (75.00%), 1 Hold (12.50%), 1 Sell (12.50%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 1 1 6 Strong Sell Sell Hold Buy Strong Buy

HRMY Forecast vs Benchmarks

TypeNameUpside
StockHarmony Biosciences16.77%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts--7
Avg Price Target--$46.14
Last Closing Price$38.82$38.82$38.82
Upside/Downside--18.86%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 2534--18
Dec, 2444--210
Nov, 2434-2211
Oct, 2434-2211
Sep, 2424-2210
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 30, 2024Corinne JenkinsGoldman Sachs$28.00$41.49-32.51%-27.87%
Oct 10, 2024Graig SuvannavejhMizuho Securities$52.00$33.6054.76%33.95%
Sep 10, 2024Ashwani VermaUBS$56.00$36.8951.80%44.26%
Aug 08, 2024Graig SuvannavejhMizuho Securities$42.00$33.5525.19%8.19%
Jun 24, 2024Francois BriseboisOppenheimer$56.00$30.3984.27%44.26%
May 01, 2024Ami FadiaNeedham$52.00$30.3771.22%33.95%
Apr 30, 2024Danielle BrillRaymond James$37.00$30.9119.70%-4.69%
Oct 14, 2022Chris HowertonJefferies$61.00$47.6328.07%57.14%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Oct 30, 2024Cantor FitzgeraldOverweightOverweighthold
Oct 30, 2024OppenheimerOutperformOutperformhold
Oct 30, 2024Goldman SachsSellSellhold
Oct 29, 2024UBSBuyBuyhold
Oct 02, 2024UBSBuyBuyhold
Sep 12, 2024NeedhamBuyBuyhold
Sep 10, 2024UBSBuyBuyhold
Sep 09, 2024UBSBuyinitialise
Aug 06, 2024NeedhamBuyBuyhold
Jun 24, 2024CitigroupBuyBuyhold

Financial Forecast

EPS Forecast

$-5 $-1 $3 $7 $11 $15 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.01$0.60$3.14$2.17-----
Avg Forecast$-0.59$0.64$2.79$2.42$2.35$3.34$4.68$6.61$11.05
High Forecast$-0.60$0.62$2.63$2.38$2.07$2.01$3.15$4.68$10.66
Low Forecast$-0.56$0.66$2.92$2.46$2.54$3.99$6.02$10.42$11.50
Surprise %240.68%-6.25%12.54%-10.33%-----

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$159.74M$305.44M$437.86M$582.02M-----
Avg Forecast$155.21M$303.77M$436.79M$582.76M$713.65M$852.00M$1.05B$1.31B$1.83B
High Forecast$150.68M$294.91M$418.27M$582.11M$713.61M$827.13M$1.05B$1.27B$1.78B
Low Forecast$159.11M$311.41M$452.88M$583.40M$713.68M$876.86M$1.05B$1.35B$1.89B
Surprise %2.92%0.55%0.24%-0.13%-----

Net Income Forecast

$-100M $60M $220M $380M $540M $700M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-51.86M$34.60M$181.47M$128.85M-----
Avg Forecast$-35.32M$121.44M$58.46M$128.85M$139.23M$206.35M$281.05M$390.23M$667.32M
High Forecast$-36.47M$93.40M$42.64M$94.40M$124.93M$121.42M$190.17M$282.54M$643.53M
Low Forecast$-33.98M$149.49M$74.29M$163.31M$153.53M$240.96M$363.44M$629.08M$694.25M
Surprise %46.83%-71.51%210.39%------

HRMY Forecast FAQ

Is Harmony Biosciences stock a buy?

Harmony Biosciences stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 1 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Harmony Biosciences is a favorable investment for most analysts.

What is Harmony Biosciences's price target?

Harmony Biosciences's price target, set by 8 Wall Street analysts, averages $45.33 over the next 12 months. The price target range spans from $28 at the low end to $56 at the high end, suggesting a potential 16.77% change from the previous close price of $38.82.

How does Harmony Biosciences stock forecast compare to the average forecast of its sector, industry, and investment themes?

Harmony Biosciences stock forecast shows a 16.77% upside, underperforming the average forecast for the healthcare stocks sector (25.20%) and underperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Harmony Biosciences over the past three months?

  • January 2025: 37.50% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 12.50% Strong Sell.
  • December 2024: 40.00% Strong Buy, 40.00% Buy, 0% Hold, 0% Sell, 20.00% Strong Sell.
  • November 2024: 27.27% Strong Buy, 36.36% Buy, 0% Hold, 18.18% Sell, 18.18% Strong Sell.

What is Harmony Biosciences’s EPS forecast?

Harmony Biosciences's average annual EPS forecast for its fiscal year ending in December is 2.35 for 2024, a 8.29% increase from the reported $2.17 in 2023. The prediction for 2025 is $3.34, $4.68 for 2026, $6.61 for 2027, and $11.05 for 2028.

What is Harmony Biosciences’s revenue forecast?

Harmony Biosciences's average annual revenue forecast for its fiscal year ending in December is $713.65M for 2024, a 22.62% increase from the reported $582.02M in 2023. The forecast for 2025 is $852M, $1.05B for 2026, $1.31B for 2027, and $1.83B for 2028.

What is Harmony Biosciences’s net income forecast?

For its fiscal year ending in December, Harmony Biosciences's average annual net income forecast is $139.23M for 2024, reflecting an 8.05% increase from the reported $128.85M in 2023. The projection for 2025 is $206.35M, $281.05M for 2026, $390.22M for 2027, and $667.32M for 2028.